Last reviewed · How we verify

NCT01909141

Combined Letrozole-metformin-pioglitazone Versus Combined Clomiphene Citrate-metformin-pioglitazone in Clomiphene Citrate-resistant Women With Polycystic Ovary Syndrome

Completed EARLY_PHASE1 Results posted Last updated 30 September 2015
What this trial tests

EARLY_PHASE1 trial testing induction of ovulation using letrozole-pioglitazone-metformin in Polycystic Ovary Syndrome in 100 participants. Completed in 1 April 2014.

Timeline
1 August 2013
Primary endpoint
1 February 2014
1 April 2014

Quick facts

Lead sponsorCairo University
PhaseEARLY_PHASE1
StatusCompleted
Study typeINTERVENTIONAL
Allocationrandomized
Designparallel
Maskingdouble
Primary purposetreatment
Enrollment100
Start date1 August 2013
Primary completion1 February 2014
Estimated completion1 April 2014
Sites1 location across Egypt

Drugs / interventions tested

Conditions studied

Sponsor

Cairo University

Who can join

Adults 20 to 40, female only, with Polycystic Ovary Syndrome or Infertility. Patients with the condition only — healthy volunteers not accepted.

What's being measured

Primary outcomes are the specific endpoints the trial is designed to prove or disprove.

Sponsor's own description

Polycystic ovary syndrome (PCOS) affects 5-10% of women in childbearing age. Hyperinsulinemia contributes to chronic anovulation commonly encountered in women with PCOS. The first choice therapy is clomiphene citrate (CC). In CC resistant cases, the American College of Obstetrics and Gynecology (ACOG) recommends the use of insulin sensitizer metformin. Other insulin sensitizing agents include rosiglitazone and pioglitazone. Pioglitazone is said to improve fertility and ovulation in patients with PCOS.CC may be associated with poor endometrial thickening due to its antiestrogenic effect. Letrozole may improve this condition. In this study we will compare the effect of combined letrozole-metformin-pioglitazone with that of combined CC-metformin-pioglitazone in ovulation induction in CC-resistant PCOS women.

Publications & conference data

3 peer-reviewed publications reference this trial (live from Europe PMC):

  1. Drug repurposing for cancer therapy.
    Xia Y, Sun M, Huang H, Jin WL. · · 2024 · cited 229× · PMID 38637540 · DOI 10.1038/s41392-024-01808-1
  2. Big Data Mining and Adverse Event Pattern Analysis in Clinical Drug Trials.
    Federer C, Yoo M, Tan AC. · · 2016 · cited 23× · PMID 27631620 · DOI 10.1089/adt.2016.742
  3. A randomized controlled trial of clomifene citrate, metformin, and pioglitazone versus letrozole, metformin, and pioglitazone for clomifene-citrate-resistant polycystic ovary syndrome.
    El-khayat W, Abdel Moety G, Al Mohammady M, Hamed D. · · 2016 · cited 21× · PMID 26613820 · DOI 10.1016/j.ijgo.2015.06.063

Verify or expand the search:

Other recruiting trials for Polycystic Ovary Syndrome

Currently open trials in the same condition.

Other Cairo University trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT01909141.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing